White Paper Download
Sponsors and clinical research organizations (CROs) are being very cautious in their utilization of adaptive clinical trial designs. And well they should be. While under the right circumstances, clinical trials can enhance the ethical treatment of patients, enable better decisions faster and help minimize the cost of clinical development, it is important to keep in mind that adaptive trials will not always be appropriate. This paper from Elsevier Business Intelligence discusses how adaptive clinical trials can provide a better way to explore and demonstrate the efficacy and safety of investigational products, while also emphasizing the point that a trial that forgoes validity for novelty is not a good trial.
Have a SAS profile? Log in to pre-fill the form.